Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

摘要: Abstract Objective: To assess whether metformin safely reduced development of gestational diabetes in women with the polycystic ovary syndrome (PCOS). Design: Prospective and retrospective study. Setting: Outpatient clinical research center. Patient(s): The prospective study included 33 nondiabetic PCOS who conceived while taking had live births; these, 28 were through delivery. 39 birth pregnancies without therapy. Intervention(s): Metformin, 2.55 g/d, throughout pregnancy PCOS. Main Outcome Measure(s): Development Result(s): Before therapy, after covariance adjustment for age, two cohorts did not differ height, weight, basal metabolic index, insulin, insulin resistance, or secretion. Both high fasting resistant, Among received metformin, developed 1 (3%) versus 8 12 (67%) their previous metformin. take 14 60 (23%) pregnancies. When all births combined, occurred 22 72 (31%) those took With as response variable age at delivery treatment group (metformin no metformin) explanatory variables, odds ratio was 0.093 (95% CI: 0.011 to 0.795). 93 0.115 0.014 0.938). Conclusion(s): In PCOS, use is associated a 10-fold reduction (31% 3%). It also reduces resistance secretion, thus decreasing secretory demands imposed on pancreatic β-cells by pregnancy.